[Alpha adrenergic blocking agents in disorders of the bladder sphincter].
M
M
Perrigot
A
A
Vannier
Y
Y
Bor
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D013948:Moxisylyte / Q000627:therapeutic use; D009530:Nicergoline / Q000627:therapeutic use; D010643:Phenoxybenzamine / Q000627:therapeutic use; D011224:Prazosin / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D001748:Urinary Bladder Neck Obstruction / Q000188:drug therapy*; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy*; D014549:Urinary Incontinence / Q000188:drug therapy; D014555:Urination Disorders / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D010643:Phenoxybenzamine; D009530:Nicergoline; D013948:Moxisylyte; D011224:Prazosin
Les alpha-bloquants dans les troubles vésico-sphinctériens.